Targeting the undruggable oncogenic KRAS: the dawn of hope

KRAS mutations are the drivers of various cancers, including non–small cell lung cancer, colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been made to inhibit KRAS mutants and oncogenic KRAS signaling using inhibitors. Recently, specific targeting of KRAS mutants wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Asimgil, Hande, Ertetik, Utku, Çevik, Nedim Can, Ekizce, Menar, Doğruöz, Alper, Gökalp, Muazzez, Arık-Sever, Elif, Istvanffy, Rouzanna, Friess, Helmut, Ceyhan, Güralp Onur, Demir, Ihsan Ekin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765045/
https://www.ncbi.nlm.nih.gov/pubmed/35014625
http://dx.doi.org/10.1172/jci.insight.153688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765045/
https://www.ncbi.nlm.nih.gov/pubmed/35014625
http://dx.doi.org/10.1172/jci.insight.153688

Ejemplares similares